SCHEMBL41787

SCHEMBL41787

Nc1nc2c(ncn2N)c(=O)[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 8/20 0.59
PNP P00491 4/20 0.55
TK1 P04183 2/20 0.55
BLM P54132 2/20 0.54
USP2 O75604 1/20 0.54
TSHR P16473 1/20 0.54
EDNRA P25101 1/20 0.54
HTR2A P28223 1/20 0.54
RECQL P46063 1/20 0.54
HBB P68871 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
CYP3A4 P08684 1/20 0.51
NFKB1 P19838 1/20 0.51
VCP P55072 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HIF1A Q16665 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28095386 0.84 XDH (0.57) XDHPNPTK1BLMUSP2
SCHEMBL986800 0.84 XDH (0.60) XDHPNPTK1BLMUSP2
SCHEMBL15005119 0.82 XDH (0.59) XDHPNPTK1BLMUSP2
SCHEMBL27667185 0.82 XDH (0.63) XDHPNPTK1BLMUSP2
SCHEMBL24499589 0.81 XDH (0.40) XDHPNPTK1BLMUSP2
SCHEMBL2051364 0.81 XDH (0.57) XDHPNPTK1BLMUSP2
SCHEMBL10835122 0.81 XDH (0.61) XDHPNPTK1BLMUSP2
9-Methylguanine SCHEMBL22884 0.81 XDH (0.58) XDHPNPTK1BLMUSP2
SCHEMBL22533906 0.81 XDH (0.57) XDHPNPTK1BLMUSP2
SCHEMBL24236963 0.81 HPGD (0.46) XDHPNPTK1BLMUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115286631-A Water phase preparation method and application of guanine twin crystal nanosheet 北京理工大学 2022-11-04 CN claimed
CN-101784556-B Thiocarbon-protecting groups for rna synthesis AGILENT TECHNOLOGIES INC 2014-07-09 CN claimed
CN-103476947-A Enhanced biodistribution of oligomers GROOVE BIOPHARMA CORP 2013-12-25 CN claimed
CN-103068834-A Phosphoramidites for reverse RNA synthesis CHEMGENES CORP 2013-04-24 CN claimed
CN-102766182-A Method for synthesizing dideoxynucleoside through glycosyl transfer reaction and application thereof JIANGYIN SULI CHEMICAL CO LTD 2012-11-07 CN claimed
US-8039611-B2 2′-hydroxyl group-modified ribonucleoside derivatives TOKYO INSTITUTE OF TECHNOLOGY (JP) 2011-10-18 US claimed
CN-1189562-C Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase GENESENSE TECHNOLOGIES INC (CA) 2005-02-16 CN claimed
CN-1160402-A Purine and guanine compounds as inhibitors of PNP CHIROSCIENCE LTD (GB) 1997-09-24 CN claimed
EP-4698674-A1 METHODS TO TREAT GLIOMA IN SUBJECTS WITH DEFINED TUMOUR MICROENVIRONMENT University Health Network (CA) 2026-02-25 EP disclosed
US-20260049318-A1 INHIBITION OF PLANT PROTEASE AED3-1 FOR IMPROVED HETEROLOGOUS PROTEIN PRODUCTION UNIV GUELPH (CA) 2026-02-19 US disclosed
EP-4615994-A1 DNAZYME FOR EOSINOPHIL PEROXIDASE AND USES THEREOF McMaster University (CA) 2025-09-17 EP disclosed
WO-2025085704-A1 BRAIN-CELL SPECIFIC PARTIAL CELLULAR REPROGRAMMING TREATMENT AND PREVENTION METHODS FOR ALZHEIMER'S DISEASE AND PROGERIA, COMPOSITIONS THEREFORE, AND USES THEREOF YOUTHBIO THERAPEUTICS INC. (US) 2025-04-24 WO disclosed
WO-2024250102-A1 FOOD PACKAGING SYSTEM FOR DETECTING PATHOGENIC BACTERIA TOYOTA TSUSHO CANADA, INC. (CA) 2024-12-12 WO disclosed
US-20240392343-A1 METHODS TO SCREEN YEAST TO IDENTIFY XENOBIOTICS THAT TARGET PESTS, PATHOGENS AND PARASITES ROY PETER J (CA) 2024-11-28 US disclosed
EP-0604409-A1 COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1994-07-06 EP disclosed
EP-0549615-A1 SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1993-07-07 EP disclosed
WO-1992003568-A1 SUGAR MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1992-03-05 WO disclosed
WO-1991010671-A1 COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION ISIS PHARMACEUTICALS, INC. (US) 1991-07-25 WO disclosed
CN-1036578-A NOVEL FLUOROPHOSPHONATE NUCLEOTIDE DERIVATIVES MERRELL DOW PHARMA (US) 1989-10-25 CN disclosed
EP-0310365-A1 Engine seal compatible dispersant for lubricating oils AMOCO CORPORATION (US) 1989-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049318-A1 INHIBITION OF PLANT PROTEASE AED3-1 FOR IMPROVED HETEROLOGOUS PROTEIN PRODUCTION DPP3, IDE, NOTCH3 XDH 4554/4885PNP 1073/4885TK1 1490/4885
US-20240392343-A1 METHODS TO SCREEN YEAST TO IDENTIFY XENOBIOTICS THAT TARGET PESTS, PATHOGENS AND PARASITES CYP4X1, CYP7A1, CYP1A1 XDH 56/4885PNP 460/4885TK1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.